biostudies-literatureUnknown11(1)Le TT<i>Morus alba</i> L. root bark (MAR, "Sang-Bai-Pi" in traditional Chinese medicine) has been traditionally used for the treatment of inflammatory disorders. Phytochemical investigation of MAR yielded 11 new flavanones and one new chalcone (<b>1</b>-<b>12</b>, morutamins A-L), along with 27 known compounds (<b>13</b>-<b>39</b>). Their structures and absolute configurations were elucidated by combining HRESIMS and NMR analyses with DP4 and DP4+ probability calculations and ECD data. Among these, morutamin L (<b>12</b>) exhibited potent anti-inflammatory and immunomodulatory activities by inhibiting epidermal growth factor receptor and toll-like receptor agonist-induced NF-κB/AP-1 activation, which were explored through network pharmacology, molecular docking, and experimental verification. SACS omega2246-2262https://www.ebi.ac.uk/biostudies/studies/S-EPMC12809818biostudies-literatureMorutamins A-L from <i>Morus alba</i> L. Root Bark with Inhibitory Effects on Epidermal Growth Factor Receptor and Toll-Like Receptor-Mediated NF-κB/AP‑1 Activation.PMC12809818Jung SHLee WBJung YTran SHLe TTCha JWKang TKBang MKang KfalseMorutamins A-L from <i>Morus alba</i> L. Root Bark with Inhibitory Effects on Epidermal Growth Factor Receptor and Toll-Like Receptor-Mediated NF-κB/AP‑1 Activation.<i>Morus alba</i> L. root bark (MAR, "Sang-Bai-Pi" in traditional Chinese medicine) has been traditionally used for the treatment of inflammatory disorders. Phytochemical investigation of MAR yielded 11 new flavanones and one new chalcone (<b>1</b>-<b>12</b>, morutamins A-L), along with 27 known compounds (<b>13</b>-<b>39</b>). Their structures and absolute configurations were elucidated by combining HRESIMS and NMR analyses with DP4 and DP4+ probability calculations and ECD data. Among these, morutamin L (<b>12</b>) exhibited potent anti-inflammatory and immunomodulatory activities by inhibiting epidermal growth factor receptor and toll-like receptor agonist-induced NF-κB/AP-1 activation, which were explored through network pharmacology, molecular docking, and experimental verification. S2026-01-01T00:00:00Z2026 Jan2026-06-10T05:27:27.046Z2026-06-10T03:07:30.334ZS-EPMC128098184155260610.1021/acsomega.5c11810